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Key points  
• Mass cytometry reveals a Treg immune signature for aplastic anemia (AA), and for 
response to ATG.  
• AA Tregs in vitro are expandable, stable and functional, with potential for future 
therapeutic options.  
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Abstract 
Idiopathic aplastic anemia (AA) is an immune-mediated and serious form of bone marrow failure. 
Akin to other autoimmune diseases, we have previously shown that in AA regulatory T-cells 
(Tregs) are reduced in number and function. The aim of this study was to further characterize Treg 
subpopulations in AA and investigate the potential correlation between specific Treg subsets and 
response to immunosuppressive therapy (IST) as well as their in-vitro expandability for potential 
clinical use. Using mass cytometry (CyTOF) and an unbiased multidimensional analytical 
approach, we identified two specific human Treg subpopulations (Treg A and Treg B) with 
distinct phenotypes, gene-expression, expandability and function. Treg subpopulation B, 
predominates in IST responder patients, has a memory/activated phenotype (with higher 
expression of CD95, CCR4 and CD45RO within FOXP3hi, CD127lo Tregs), expresses the IL-
2/STAT5 pathway and cell-cycle commitment genes. Furthermore, in-vitro expanded Tregs 
become functional and with the characteristics of Treg subpopulation B. Collectively, this study 
identifies human Treg subpopulations that can be used as predictive biomarkers for response to 
IST in AA and potentially other autoimmune diseases. We also show that Tregs from AA patients 
are IL-2 sensitive and expandable in-vitro, suggesting novel therapeutic approaches such as low 
dose IL-2 therapy and/or expanded autologous Tregs and meriting further exploration.  
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Introduction 
Treatment options for idiopathic aplastic anemia(AA) include allogeneic hematopoietic 
stem cell transplantation (HSCT) or immunosuppressive therapy (IST), and recently eltrombopag 
for refractory severe AA.1-3 Some patients are ineligible for HSCT due to older age or lack of a 
suitable donor, and following IST a third of patients fail to respond and 35% relapse after 
responding. Up to 20% of patients transform to myelodysplastic syndrome (MDS) or acute 
myeloid leukemia (AML) after IST3-7. Additional novel therapeutic approaches are needed for AA 
patients who fail to respond to IST, and alongside this, more robust diagnostic tests that predict 
response to IST. 
We, and others, have shown a reduction in the number and function of Tregs in AA8-11. 
Tregs from AA patients also secrete pro-inflammatory cytokines8. Correlation between number 
and function of Tregs and response to standard IST has not been fully investigated, and it is 
unclear whether the dominant Treg subpopulation in AA is more of a T conventional(Tcon) subtype 
or are genuinely functional Tregs.  
The aims of this study were (i) to identify an immune signature for AA compared to healthy 
individuals, based on Treg subpopulations and Tcon (ii) to identify the immune signature that 
predicts response to IST at time of diagnosis of AA and (iii) to examine the expandability and 
characteristics of Treg subpopulations that may form the basis for novel therapeutic approach to 
AA patients who are refractory to IST. For this, we utilized a novel deep-phenotyping strategy 
using multi-parameter mass cytometry (known as cytometry by time-of-flight (CyTOF)) and 
automated clustering method including t-distributed stochastic neighbour embedding (t-SNE)12 to 
visually (viSNE) identify cell populations13 in combination with spanning-tree progression 
analysis of density-normalized events (SPADE)14. This enabled us to identify two distinct 
subpopulations of human Tregs in AA and healthy age matched donors (HDs), and to demonstrate 
clear differences in AA that predicted response to IST. We also showed that AA Tregs can be 
expanded in-vitro and that they are stable and functional. 
Methods 
Patients and healthy donors 
Thirty-nine AA patients at diagnosis and 31 HDs were recruited(summarized in table-1). 
Peripheral blood mononuclear cells(PBMCs) from 16 patients (12 IST-responder and 4 non-
responders) were used for initial CyTOF analysis and samples from another 15 patients(11 IST-
responders and 4 non-responders) were used as validation cohort. PBMCs from additional 8 
patients were used for functional assays in addition to 4 patients from the initial cohort. Response 
to IST was evaluated at 6 months post-therapy. Median age was 45 years (range 20-72 years). IST 
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eligible AA patients were randomly invited to participate in this study prior to commencement of 
therapy.  All patients< 35 years old were screened for Fanconi anemia.  
Antibodies and cell staining  
We designed a panel of antibodies based on surface markers, transcription factors and cytokines 
(table-s1). Each antibody was tagged with a rare metal isotope and its function verified by 
conventional flow-cytometry prior to mass-cytometry (supplementary methods). CyTOF-2 mass 
cytometer(Fluidigm) was used for data acquisition.  Acquired data were normalized based on 
normalization beads (Ce 140, Eu151, Eu153, Ho165 and Lu175).15 Automated clustering was 
performed on a subset of 800,000 cells sampled from all individuals. The number of cells sampled 
from each individual was proportional to the total number of cells in that sample. Collected cells 
were stained with metal conjugated antibodies with or without a 4-hour stimulation with phorbol 
myristate acetate (PMA) and ionomycin in the presence of brefeldin. Intracellular staining for 
transcription factors and cytokines was performed after fixation and permeabilization according to 
manufacturer's instructions (eBioscience). Conventional flow-cytometry data were analyzed by 
polychromatic flowcytometer (LSRFortessa, BD biosciences).  
Data processing, scale transformation, automated clustering and distance computations 
Data were initially processed and analyzed using Cytobank.16 The stand-alone analysis tool 
cyt was also used for performing t-SNE dimensionality reduction and merging distinct FCS files13.  
We analyzed mass-cytometry complex data using viSNE12 to visually identify delineate 
subpopulations13 in combination with SPADE14 and heatmaps15.  To distinguish CD4+ T-cell 
subpopulations, in particular Tregs.15 See the supplementary material and methods. 
Treg expansion 
Freshly isolated live Tregs were stimulated with anti CD3/CD28 beads(1:1 ratio) 
(Dynabeads human T-activator CD3/CD28, Life Technologies) and high dose(1,000 IU/ml) 
interleukin-2 (IL-2)(Proleukin, Novartis) for four weeks with all-trans retinoic acid(ATRA) 2 μM 
(Sigma Aldrich) and rapamycin(Rapa) 100 nM(Alfa-Aesar). Culture medium (XV Prime, Irvine 
Scientific supplemented with AB serum 10%) and beads was replenished every week. After 4 
weeks of expansion, cells were rested with decreasing doses of IL-2 for 5 days.17 
 
DNA methylation analysis by deep amplicon bisulphite sequencing 
DNA isolation method, primer sequences and cycling conditions are included in 
supplementary material and methods and figure-MS1. 
T-cell receptor diversity 
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Amplification and sequencing of [TCRB/IGH/IGKL/TCRAD/TCRG] CDR3 was 
performed using immunoSEQ Platform (Adaptive Biotechnologies, Seattle, WA), as previously 
described(supplementary methods). Power Geometric (PG) index with Horvitz-Thompson type 
was used as correction for under-sampling and Good-Turing coverage adjustment18,19,20.  
Gene expression 
RNA extraction method is included in supplementary methods. Analysis of differential 
gene expression was performed as previously described21,22(supplementary methods).  
GEP data of this manuscript is deposited at gene expression omnibus(GEO), accession 
number: GSE78004  
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=qvclwscgnxgvtkz&acc=GSE78004 
Statistical analysis 
Different statistical methods have been used which are explained in the result section 
and/or figure legends.  P < 0.05 was considered as statistically significant in all cases. Statistics 
were calculated using SPSS version 22 or R version 3.2.2.  
Study approval 
King's College Hospital Local Research Ethics Committee and Institutional Review Board 
of the National Heart, Lung, and Blood Institute (NIH) approved the clinical studies of IST and 
sample collection, and informed written consent was obtained from patients.  
 
Results 
 Identification of an immune signature for AA compared to healthy individuals based 
on distinct Treg subpopulations  
We analyzed 31 AA patients at diagnosis and 5 HDs. Of these 31 patients, 16 were part of 
an initial test cohort and a further 15 as validation cohort. Metal-tagged antibodies against surface 
and intra-cellular markers were used in 2 separate panels (with or without stimulation with 
PMA/Ionomycin) to stain T-cells, including known markers for Tregs (CD25, CD127, FOXP3), 
naïve/memory subsets, homing/trafficking receptors, and differentiation/activation markers (table-
S1). CD4+, CD8+ T-cells and B cells were clustered using this “whole panel” clustering approach 
(34 markers in panel 1 (table S1)) to minimize bias. FOXP3+ cells were also clustered within 
CD4+ T-cells (figure-1 and figure-S1). After gating for CD3+, CD4+, CD8- and merging all 
samples, viSNE was performed and cells clustered, based on 13 markers which most clearly 
clustered Tregs (figures-2&S2). Treg subpopulations were clustered together and identified by 
high expression of CD25 and FOXP3 and low expression of CD127 (figure-2a and figure-S1b). 
Identified Tregs expressed CD27hi, CD45RAlo, CD45ROhi, CD95hi, CD7lo, CD28hi, CCR4hi 
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compared to the total CD4+ T-cell subpopulation (figure-2b). The frequency of total Tregs was 
significantly lower in AA patients compared to HDs (2.7 % v 5.7% of CD4+ T-cells, p<0.01) 
confirming our previously published findings8. The numbers of Tregs were not significantly 
different between patients with severe (SAA)/ very severe AA(VSAA) and non-severe 
AA(NSAA). 
Although viSNE clustered the Treg population in one area, density plots revealed a 
heterogeneous distribution of cells. Two subpopulations within Tregs with different frequency 
between AA and HDs were identified and designated as “Treg A” and “Treg B” (figure-2c&d and 
figure-S1b&c). To confirm the presence of these two subpopulations and eliminate any bias, 
dimensionality reduction and automated unsupervised clustering methodology was applied 
independently by the bioinformatician that confirmed the presence of two subpopulations within 
Tregs (figure-2c and figure-S1b&c). These two subpopulations showed distinct markers in AA 
Tregs (16 patients, 12 IST-responder and 4 non-responders) as well as 5 HDs. While both 
subpopulations were CD25hi and FOXP3hi and CD127lo compared to total CD4+ T-cells, 
subpopulation B was additionally characterized by a lower expression of CD45RA (p<0.0001), 
CD7 (p<0.001), CD27 (p<0.05) and higher expression of CCR4 (p<0.0001), CCR6 (p<0.0001), 
CD25 (p<0.0001), CD28 (p<0.01), CD45RO (p<0.0001), CD95 (p<0.0001), CXCR3 (p<0.05), 
FOXP3 (p<0.0001) and HLA-DR (p<0.0001) compared to subpopulation A (Kruskal–Wallis one-
way analysis of variance by ranks).  
In addition to total Tregs, percentage of subpopulation B Tregs was significantly lower in 
AA patients compared to HDs(40.8%±13.7% v 72.2%±15, p=0.008).  
Treg composition predicts response to IST at time of diagnosis of AA 
When patients were stratified into IST-responders (n=12) and non-responders (n=4), while 
the overall frequency of Treg B was lower in both responder and non-responding patients at time 
of diagnosis compare to HDs (n=5) (48.8%±6.1 & 28.9%±2.7 v 72.2%±6.7, p=0.005, p<0.0001), 
non-responders had significantly higher Treg A and lower Treg B cells compared to responders 
(63.5%±4.5 v 38.8%±5.0, p<0.005 for Treg A, 28.9%±2.7 v 48.8%±6.1, p<0.05 for Treg B) 
(figure-2e and table-2).  
To investigate the overlap between the Treg subpopulations with Treg subpopulations 
identified by Miyara et al23, Tregs were gated based on CD45RA and FOXP3 expression. While 
subpopulation A and B mainly overlapped with subpopulations I (CD45RAhi, FOXP3lo) and II 
(CD45RAlo, FOXP3hi), respectively, subpopulation III (CD45RAlo, FOXP3lo) was spread over 
both population A and B area and some cells clustered outside Treg area(figure-2f).  
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Following IST response, the frequency of population A was significantly reduced in 
responders (from 38.8%±5.0 to 19.2%±2.4, p<0.01), but not significant in non-responder patients. 
Treg B frequency was significantly higher in responders compared to non-responders (59.9%±3.4 
v 21.8%±4.3, p<0.0001) and closer to HDs (table-2). Treg population A or B were not 
significantly different between patients with severe/ very severe (n=11) and non-severe AA (n=5). 
The cytokine profile of Tregs following stimulation with PMA, Ionomycin and Brefeldin-
A was investigated. Treg subpopulations A and B were identified within Tregs (figure-S3). 
Stimulated Treg clusters expressed higher CD25 (p<0.001) and FOXP3 (p=0.001) and lower 
CD127 (p=0.001) compared to total CD4+ T-cells. Majority of CD4+ T-cells with pro-
inflammatory cytokine properties clustered outside the “Treg area”. Thus, Treg clusters expressed 
negligible amounts of pro-inflammatory cytokines IFN-γ, and IL-17 (figure-3a). Tregs expressed 
significantly higher IL-10 compared to total CD4+ T-cells (p=0.002), however the IL-10 
expression was not significantly different between the two Treg subpopulations. Although TNF-α 
expressing cells were clustered within non-Treg subpopulations, a cluster of CD4+ TNF-α+ T-cells 
clustered within Treg A subpopulation  (figure-3b). These TNF-α+ cells expressed significantly 
higher CD127 (p<0.001), and lower IL-10 (p<0.001), CD279 (p<0.001), HLA-DR (p=0.003), 
CD38 (p<0.001), CD25 (p<0.001) and FOXP3 (p<0.001) compared to total Tregs. Although at 
time of diagnosis the frequency of TNF-α+ cells was not significantly different between IST 
responders and non-responders, IST responders had significantly lower TNF-α+ cells compared to 
non-responder patients following  response to IST (0.32% v 1.81%, p=0.008)(figure-3c). 
Validation by conventional polychromatic flowcytometry 
Conventional flow-cytometry was performed on PB from a separate validation cohort of 15 AA 
patients (11 IST responders and 4 non-responders) at time of diagnosis to confirm that the 
identified markers were sufficient to detect Treg subpopulations and whether the cytof -identified 
combination of markers was still predictive for IST response. PBMCs were stained with anti-CD4, 
CD25, CD127, FOXP3, CD95, CCR4 and CD45RA and similar to the initial cohort, Treg A were 
significantly higher in non-responders compared to responders (37.82%±5.11 v 18.33±2.31, 
p=0.006) whereas Treg B were significantly higher in responders (69.97%±3.02 v 49.34%±4.92, 
p=0.01)(figure-S4). 
Conventional CD4+ T-cells 
Our marker panels also identified and clustered conventional CD4+ T-cells (Tcon). The 
Treg population was first gated out on viSNE plot and SPADE clustering based on CD45RA, 
CD45RO, CD27 and CD62L performed. Tcon subpopulations were defined as naïve (CD45RA+ 
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CD45RO- CD27hi), memory (CD45RA- CD45RO+ CD27lo), central memory (CD45RA- 
CD45RO+ CD27lo CD62Lhi), effector memory (CD45RA- CD45RO+ CD27lo CD62Llo), effector 
(CD45RA- CD45RO+ CD27lo) and terminal effectors (CD45RA- CD45RO- CD27lo).Subset 
frequencies were not significantly different between IST-responders (n=12) and non-responders 
(n=4) at time of diagnosis. However, effector CD4+ T-cells (Te) expressed significantly higher 
CD161 level in non-responders compared to responders (p<0.01) (figure-3d&e and table-S2). 
Function, ontogeny and in-vitro expansion of Treg subsets 
To assess function of the Treg subpopulations, HD CD4+ Tregs were sorted based on 
CD25, CD127 and CD95 expression, that showed highest expression differences between 
subpopulation A and B on viSNE clusters, excluding intracellular markers to avoid fixation and 
permeabilisation of the cells. Sorted cells were CD4+CD25hi CD127lo CD95-, CD45RAhi, CCR4lo 
(subpopulation A) and CD4+CD25hi CD127lo CD95+, CD45RAlo, CCR4hi (subpopulation B). To 
confirm these markers were enough to identify Treg subpopulations, viSNE runs were performed 
based on the above markers and identified both subpopulations (figure-S5). Tregs B were 
significantly more functional compared to subpopulation A, in suppression of both IFN-γ and 
TNF-α secretion by T conventional (p<0.05, figure-4a). 
Genomic DNA from sorted Tregs A and B was used for T-cell receptor (TCR) Vß chain 
complementarity determining regions (CDR3) high-throughput sequencing 19,20. On average, 
subpopulation A and B had 33773 and 26090 unique TCR sequences, respectively, and 233 
sequences were common to both (r=0.008) (figure-S6). Tcon also shared 137 and 383 sequences 
with subpopulation A and B respectively (r=0.154 and r=0.092 respectively). It is recognized that 
in assessment of naturally, highly diverse TCR subpopulations, under-sampling can introduce 
bias18 24. We therefore used Power Geometric index (PG) for pairwise comparison of TCR 
repertoire overlap18. Overlap between Treg A, B and Tcon was small suggesting these 
subpopulations were distinct (figure-4b).  
Global gene expression (GEP) analysis of Treg subpopulations  
Whole GEP data25,26 showed both Treg A and Treg B had different GEP compared to Tcon. 
Nevertheless, when principle component analysis (PCA) was performed, Treg B and Tcon had the 
highest difference while Treg A subpopulation showed a transcriptional profile in between Treg B 
and Tcon (figure-S7). 
Comparing GEPs of Treg subpopulations to Tcon, using the human Treg’s gene-signature, 
27
, showed both Treg A and B subpopulations were significantly enriched in genes up-regulated in 
human Tregs including: IL-2RA, FOXP3, IKZF2, TIGIT and CTLA4 (FDR<0.0001 for both Treg 
subpopulations compared to Tcon. Treg B cells were enriched with Treg-related memory/activation 
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genes compared to Treg A, - JAKMIP1, CCR8, TRIB1 and GZMK (FDR<0.0001, figure-4c-e). 
Thus, while both Treg subpopulations were enriched with Treg associated genes, Tregs B were 
characterized by an activation gene signature in agreement with mass-cytometry findings.    
 Gene set enrichment (GSEA) functional analysis22 highlighted several genesets as 
significantly overexpressed in Treg B subpopulation including: G2M checkpoint (FDR<0.0001), 
mitosis (FDR=0.015), M phase of mitotic cell-cycle (FDR=0.018) IL2-STAT5 signaling 
(FDR=0.023) and immune response genes (FDR=0.032) (table-3). Protein interaction networks of 
proteins encoded by mRNA that are enriched in Treg B subpopulation were also mapped (see 
supplement and figures S8a&b). Ontology analyses of the functions of these protein complexes 
(table-S3 and figure-S9) showed they are involved in mitotic functions, DNA replication and cell-
cycle-dependent transcription. MKI67 mRNA (encodes nuclear Ki67 protein) was enriched in 
Treg B subpopulation. This is important as Ki67 protein is often used as a marker of proliferating 
cells 28,29.  
Expandability of Tregs in Treg promoting culture 
One of the aims of this study was to investigate the potential expandability of Tregs in AA. 
We first tested the IL-2 sensitivity of AA total Tregs based on STAT5 phosphorylation.30 Freshly 
isolated PBMCs from two HDs and six AA patients (3 IST-responders and 3 non-responders, at 
diagnosis) were cultured in the presence of IL-2 at different concentrations (from 0.1 to 1000 
IU/ml). Treg p-STAT5 expression significantly increased after 15 minutes culture with IL-2 (0.5 
IU/mL) (median fluorescence intensities (MFI) 92.6±35.1 pre IL-2 versus 787±109.6 post IL-2, p 
< 0.001) confirming their responsiveness to IL-2. There was no difference between HDs and AA 
Tregs in response to IL-2 (figure-5a).  
To test their in-vitro expandability, Tregs were obtained from 6 AA patients (3 IST-
responders and 3 non-responders, at diagnosis) and 8 HDs and were cultured and stimulated with 
anti CD3/CD28 beads (1:1 ratio) and high dose IL-2 (1,000 IU/mL) for four weeks with added all-
trans retinoic acid 2 μM and rapamycin 100 nM.17 AA Tregs expanded in a comparable rate to HD 
Tregs, with median 33 fold increase (range 29-149) compared to 21 fold increase (range 8-36) in 
HD. Expanded Tregs demonstrated more than 90% FOXP3+ expression in both AA and HDs 
(figure-5 b&c).  
Expanded Tregs were gradually (within 5 days) deprived of IL-2 following expansion and 
p-STAT5 evaluated in both AA and HDs Tregs to assess IL-2 dependency. Although expanded 
AA Tregs showed slightly lower p-STAT5 level following IL-2 deprivation, they responded to 
low dose IL-2 and p-STAT5 and returned to a similar level as in HDs(data not shown).  
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Expanded Tregs function, methylation status of TSDR and TCR diversity 
To assess the suppressive activity of expanded Tregs, Tcon were stained with a fluorescent 
proliferation dye (CellTrace Violet, Life Technologies) and co-cultured with autologous expanded 
Tregs (1:1 ratio) for 5 days in the presence of anti CD3/CD28 beads (Tcon:Treg:beads=20:20:1). 
Expanded AATregs suppressed proliferation of CD4+ Tcon (an average reduction from 43% to 5%, 
p = 0.009) in both autologous and allogeneic conditions(figure-5d). The suppressive activity of 
AA expanded Tregs was not significantly different from HD expanded Tregs.  
To assess stability of expanded Tregs, we investigated the methylation status of 15 CpG 
sites within the FOXP3 Treg-specific demethylated region (TSDR)31 by amplicon sequencing of 
bisulfite treated DNA on an Illumina MiSeq sequencing platform. TSDR CpG sites in expanded 
HDs and AA Tregs were >98% unmethylated, confirming stability of expanded Tregs(figure-6a). 
TCR Vß CDR3 high-throughput sequencing of expanded Tregs was used to investigate 
their clonality. The normalized Shannon entropy of expanded Treg repertoire was used to 
calculate the degree of clonality which on average was 0.12 (four expanded Tregs, 1 being the 
most clonal and 0 the most TCR diversity). Both AA and HDs expanded Tregs showed a 
comparable level of TCR Vß CDR3 diversity, as defined (methods S)(figure-6b). 
The (dis)similarity of in-vitro expanded Tregs with Treg A and Treg B was next 
investigated. As the isolated Tregs were stimulated and treated in a Treg skewing environment, the 
expression level of some markers like CD25 or FOXP3 were high in expanded Tregs, making it 
difficult to cluster expanded Tregs with Treg A or B of untouched Tregs for comparison. To 
overcome this technical issue, we used an alternative analysis approach based on distance 
calculation and relative expression of markers. Subpopulation of Tregs expanded in-vitro were 
assessed using the Euclidian distance between the mean expression for each parameter in Treg A 
and B (figure-6c and S10).   
Using a one tail Welch Two Sample t-test we rejected the null hypothesis that the distance 
between Treg A and expanded Tregs is lower than Treg B (p<2.2 x 10-16), suggesting that 
expanded Tregs were more similar to subpopulation B than A. 
 
 
Discussion  
Although the importance of Tregs in the pathophysiology of autoimmune diseases is well 
established, the definition and significance of Treg subpopulations is less clear. Identification of 
Treg subsets is challenging in autoimmune diseases as the number of Tregs is usually low and 
Tregs may express aberrant markers, and gating strategies for Treg subpopulations are often 
subjective. Biomarkers that, first, identify AA patients from HDs and, second, identify at time of 
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diagnosis who are less likely to respond to IST, have as yet not been identified. It is now possible 
to comprehensively characterize rare, complex populations of cells with minimal bias15,32 using 
mass-cytometry (CyTOF) to measure the expression level of more than 40 parameters at the single 
cell level32,33,34. The complexity of Treg subsets in HDs has been previously demonstrated by 
mass-cytometry on sorted Tregs35, however, their biological importance has not been investigated. 
In current study, by using this multidimensional phenotyping and unbiased approach, two distinct 
Treg subpopulations were characterized in HDs and AA patients and the changes in these subsets 
predicted response to IST at diagnosis of AA. We sorted these cells based on their immunological 
markers and confirmed their dissimilar TCR, gene expression signatures and function. Our 
analytical strategy eliminated the unavoidable subjectivity of Treg subpopulation definition based 
on two-dimensional gating without unnecessary over-clustering.  
Within the CD25hi, FOXP3hi and CD127lo Treg population, AA Tregs expressed CD27hi, 
CD45RAlo, CD45ROhi, CD95hi, CD7lo, CD28hi, CCR4hi compared to the total CD4+ T-cell. We 
have identified two well-defined subpopulations within this Treg population, (‘Treg A and B’). 
While total Treg numbers were reduced in AA, Treg A was significantly higher in AA patients 
compared to HDs.  In contrast, the number of Treg B subpopulation was significantly lower in AA 
patients compared to HDs (table 2). Subpopulation B was characterized by a lower expression of 
CD45RA, CD7, CD27 and higher expression of CCR4, CCR6, CD25, CD28, CD45RO, CD95, 
CXCR3, FOXP3 and HLA-DR. The most significantly different markers were CD95, CCR4 and 
CD45RO36-38. The identified Treg subpopulations were compared to established Treg 
subpopulation definitions23. While Treg A and B overlap with Treg subpopulations I and II 
respectively, our approach demarcates those Treg III cells which are closer to Tregs and combine 
them with subpopulation A or B based on their phenotype and eliminate cells which are closer to 
Tcon and less likely to be regulatory. There is an unmet need for more robust predictive factors for 
response to IST at time of diagnosis of AA. Known predictive factors for response to IST include 
less severe disease, young age, and absolute reticulocyte and lymphocyte counts of ≥ 25 and ≥ 1.0 
x 109/l, respectively 39. Short telomeres in children, but not in adults, also predict response to IST 
40,41
. The presence of a PIGA mutation predicts for response to IST, as does a somatic 
BCOR/BCORL mutation. In contrast, somatic mutation of DNMT3A or ASXL1 is associated with 
worse outcomes following IST42. We have identified an immune signature that predicts for 
response to IST for an individual patient at time of diagnosis of AA. Non-responders to IST were 
more likely to have higher Treg A compared to non-responders, whereas responders had higher 
Treg B numbers compared to HDs(figure-7). Treg B subpopulation characterized by a more 
“activated/memory” phenotype. We also tested this combination of identified markers in a 
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separate validation cohort of AA patients, using conventional flow-cytometry, and confirmed the 
predictive value of this combination for response to IST.  
To explore the potential therapeutic application of expanded Tregs in the treatment of AA, 
we examined the characteristics and in vitro expandability of the Treg subpopulations in depth. 
Both AA and HDs Tregs were sensitive to IL-2 as assessed by STAT5 phosphorylation. The 
expansion rate of AA Tregs (three of them from IST non-responders) was not different from HDs 
after 4 weeks culture. Expanded Tregs were functional in both autologous and allogeneic settings, 
and TSDR of expanded Tregs indicated a stable phenotype. Treg B population was more 
functional in suppressing IFN-γ and TNF-α secretion by Tcon compared to Treg A cells. Although 
both Treg subpopulations were significantly enriched with Treg specific genes such as IL-2RA, 
FOXP3, IKZF2, TIGIT and CTLA4 compared to Tcon, nevertheless, TCR sequence overlaps 
between Treg A, Treg B and Tcon were minimal, suggesting possible distinct developmental 
origins. Functional GEP analysis revealed marked enrichment of Treg B subpopulation with G2M 
checkpoint and mitosis related genes suggesting that Tregs B are more prone to enter cell-cycle. In 
studies of human primary lymphocytes and CD34+ cells, we showed that quiescent (G0) cells do 
not contain many proteins required for cell proliferation (e.g. DNA synthesis and mitosis) or 
molecules that regulate cell-cycle 43-45 46,47. Expression of mRNA encoding proteins involved in 
mitosis, DNA replication and other proliferation functions suggest that the Treg B subpopulation 
is more likely to be proliferating, primed to proliferate or they have recently exited the cell-cycle. 
The limitation of this study was the very low number of Tregs in AA patients, which made it 
technically difficult to individually assess the IL-2 sensitivity and in-vitro expandability of 
patient’s Treg subpopulations. Nonetheless, the observation that IST-responder patients had a 
significantly higher frequency of Treg B following IST therapy compared to IST non-responders 
would support the hypothesis that Treg B are more likely to proliferate and perhaps better control 
the immune response in AA, particularly following treatments with ATG-based 
immunosuppressive therapy, when the number of T cells are reduced and the ability of Tregs to 
proliferate would be crucial to reinstate a balanced immune-response (figure 7). 
In-vitro expansion of Tregs for clinical use is an emerging cellular therapy in GVHD, type-
I diabetes and organ transplant rejection.48-52 Nevertheless, the quality control of expanded Tregs 
is a time consuming procedure. Our data comparing expanded Tregs with pre-expansion Treg 
subpopulations could provide a robust and quick screening for quality control of cell therapy 
products, and may serve as a predictive tool for expandability of Tregs in AA and other 
autoimmune diseases. 
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In summary, we have shown for the first time that a novel strategy for multidimensional 
deep-phenotyping can reliably identify an immune signature for AA based on Treg 
subpopulations. This approach also identifies an immune signature that predicts for response to 
IST at time of diagnosis of AA, and which may allow a more patient specific approach to future 
treatment decision-making in SAA. Our findings also pave the way for future novel therapeutic 
approaches such as expanded autologous Tregs and low dose interleukin-2 in AA.  
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Tables 
Characteristic Value 
Number of patients 39 
Median age, y (range) 45 (20-72) 
Gender 
M 
F 
  
19 
20 
Disease severity at diagnosis 
VSAA 
SAA 
NSAA 
  
11 
16 
12 
PNH clone at the time of study 
Yes 
No 
  
28 
11 
Size of PNH clone, % (range) 
Red cells 
Granulocytes 
Monocytes 
  
0.402 (0-87.3) 
3.86 (0-96.7) 
4.517 (0-91.8) 
Etiology 
Idiopathic 
  
39 
Response to treatment 
CR 
PR 
NR 
  
6 
19 
14 
y: years, M: male, F: female, VSAA: very severe aplastic anaemia, SAA: severe aplastic 
anemia, NSAA: non-severe aplastic anemia, PNH: paroxysmal nocturnal hemoglobinuria, 
CR: complete response, PR: partial response, NR: non-response 
 
 
Table 1. Patients’ characteristics: Thirty-nine AA patients were recruited in this study and PB samples 
were used for mass-cytometry and/or in-vitro experiments. AA patients who were eligible for IST were 
randomly selected and invited to participate in this study. A small to moderate PNH clone was detected in 
28 patients, with no cases of hemolytic PNH.  
Peripheral blood mononuclear cells (PBMCs) from 16 patients (12 IST responder and 4 non-responders) 
were used for initial CyTOF analysis and samples from another 15 patients (11 IST responders and 4 non-
responders) were used as validation cohort. PBMCs from additional 8 patients were used for functional 
assays.  Among non responder patients (n=14), 7 patients were transplanted later on and the remaining 
were treated with CsA and supportive care.   
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Treg 
subpopulation Markers 
Healthy 
Donors 
IST 
 responder 
AA pre-
treatment 
IST 
Non-
responder 
AA pre-
treatment 
IST 
responder AA 
post-
treatment 
IST 
Non-
responder 
AA post-
treatment 
Treg A 
CD45RA↑ CD7↑ 
CD27↑ CCR4↓ 
CCR6↓ CD25*↓ 
CD28↓ 
CD45RO↓CD95↓ 
CXCR3↓ 
FOXP3*↓ HLA-
DR↓ 
Minor 
population 
20.3%±6.5 
↑38.8%±5.0 ↑↑ 63.5%±4.5 ↓19.26%±2.43 
NSC 
73.9%±6.8 
Treg A 
(TNF-a +) 
TNF-a + IL-10↓ 
CD279↓  
HLA-DR↓ 
CD38↓ 
R 
1.2%±0.3 
NSC 
0.75%±0.14 
NSC 
0.79%±0.13 
↓0.32%±0.12 
NSC 
1.81%±0.19
Treg B 
CD45RA↓ CD7↓ 
CD27↓ CCR4↑ 
CCR6↑ CD25‡↑ 
CD28↑ 
CD45RO↑CD95↑ 
CXCR3↑ 
FOXP3‡↑  
HLA-DR↑ 
Major 
population 
72.2%±6.7 
↓48.8%±6.1 ↓↓ 28.9%±2.7 
 NSC 
59.98%±3.18 
NSC 
21.8%±4.3 
 
Table 2. Treg A and B markers and summary of changes in AA: Surface and intracellular markers which 
are significantly higher or lower in Treg subpopulations as well as their frequencies in healthy donors, IST 
responder and non-responder AA patients prior and after IST. 
*Lower expression compared to Treg B subpopulation. 
‡Higher expression compared to Treg A subpopulation. 
R: reference value, NSC: no significant change
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Geneset FDR q-value  
Normalized 
Enrichment Score (NES) Significant genes 
G2M checkpoint <0.0001 2.0188198 
CASC5, NUSAP1, CENPE, 
TPX2, TOP2A, KIF11, BARD1, 
EZH2, SLC7A5, HN1, GINS2, 
CKS2, BUB1, SMC4, STIL, 
BRCA2, CHEK1, SAP30, 
E2F3, MKI67, CDKN2C, 
NEK2, KIF15, KPNA2, KIF23, 
ZAK, POLQ, WHSC1, TFDP1, 
UCK2, E2F2, CDKN3, CDC7, 
E2F1, AURKA, CDC20, 
EFNA5, KIF4A, EXO1, 
CDC25A , PRC1, KIF5B 
Mitosis 0.014934987 2.020 
NCAPH, NUSAP1, NDC80, 
CENPE, BUB1B, TPX2, 
KIF11, TTN, BUB1, NEK2, 
SMC4, PCBP4, PAM 
M phase of mitotic 
cell cycle 
0.01755665 2.0006573 
NCAPH, NUSAP1, NDC80, 
CENPE, BUB1B, TPX2, 
KIF11, TTN, BUB1, NEK2, 
SMC4, PCBP4, PAM 
IL2-STAT5 signaling 0.02301426 1.5519865 
SYT11, CCR4, TNFRSF9, 
CST7, ADAM19, IL1R2, 
ANXA4, PHLDA1, SLC1A5, 
IL18R1, FGL2, TNFRSF18, 
TNFRSF4, GALM, CXCL10, 
BATF, SPP1, TNFSF10, 
PHTF2, CD86, AHNAK, IL10, 
LIF, TLR7, F2RL2, CD79B, 
CTLA4, FURIN, TNFRSF1B, 
CAPG, ALCAM, CSF1, CASP3, 
CSF2, MUC1, MYO1E RORA, 
ITGAV, PRNP, ICOS, UCK2, 
CYFIP1, SOCS1 
Immune response 
genes 
0.031976275 1.9183398 
IL7, CCR2, CCR8, CCR4, 
IL1R2, CCR6, CST7, CCL20, 
GZMA, CADM1, AIM2, CIITA, 
CCR5, CTSC, IL12A, NCF4, 
IL4, CCR9, GEM, IL32, 
TNFRSF4, LAX1, DEFB4A , 
FCGR3B, TLR7, CD74, 
APOA4, CCL5, APOBEC3G, 
CD79B, CTLA4 
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Table 3. Genesets which are upregulated in Treg population B compared to population A: The most 
significant genesets which are up-regulated in Treg B subpopulation compared to Treg A are listed in this 
table. Leading edge analysis revealed several genes that significantly contribute in each genesets and 
enriched in Treg B compared to Treg A (marked as significant genes). 
 
 
 
. 
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Figure legends 
Figure 1. Peripheral blood mononuclear cell staining and clustering: PBMCs from AA and HDs 
were clustered using 34 surface and intracellular markers as our panel 1 (table S1). Intact cells 
were gated based on Ir-191 and event length, followed by Ir-191 and Ir-193 gating. Viable cells 
were selected based on CD45 expression and negativity for Rh. All FCS files were first 
normalized using control beads and analyzed using Cytobank web-based software (see the 
material and methods). CD4+, CD8+ T cells and B cells clustered together in both aplastic anemia 
(AA) and healthy donor (HD).  Figures are representatives of 16 AA and 5 HDs samples. 
Figure 2. Identification of Treg subset by automated clustering. 
A) After initial gating for CD3+, CD4+ and CD8- T cells, the gated cells were clustered using 
viSNE (Cytobank). Treg population was identified based on high expression of CD25 and FOXP3 
and low CD127 expression. 
B) Median expression of the 7 most discriminative parameters between Total CD4+ cells and 
Tregs as identified by the automated clustering algorithm FLOCK on a subset of 700,000 cells 
proportionally selected from all samples. Tregs were defined as clusters whose median expression 
was simultaneously higher than the 90% quantile of FOXP3 expression, higher than the 90% 
quantile of CD25 expression and lower than the 50% quantile of CD127 expression across all 
CD3+CD8- cells. Heatmap plot is based on 19 AA samples (pre and post IST) and 5 HDs samples.  
C) Median expression of the 8 most discriminative parameters between the two subpopulations of 
Tregs identified by the automated clustering algorithm FLOCK. Expression values were asinh-
transformed using a cofactor of 5.  Heatmap plot is based on 19 AA samples (pre and post IST) 
and 5 HDs samples.  
D) The density plot of viSNE plots revealed 2 subpopulations within Tregs, designated as Treg A 
and B (arrows). The frequencies of Treg A and B were different between healthy donors (HDs) 
and AA patients. Patients who did not respond to immunosuppressive therapy (IST NR) had 
higher number of Treg A at time of diagnosis compared to responder patients (IST R) and HDs. 
The right viSNe plots are overlay of Tregs’ contour plots colored by density and CD4+ T cells 
uncolored contour plots. 
E) At time of diagnosis and prior to treatment, Treg A frequency was higher in responder as well 
as non-responder patients compare to HDs (38.8%±5 & 63.5%±4.5 v 20.3%±6.6, p<0.05, 
p<0.0001). Whereas the frequency of Treg B was lower in both responder and non-responder AA 
patients at time of diagnosis compare to HDs (48.8%±6.1 & 28.9%±2.7 v 72.2%±6.7, p=0.005, 
p<0.0001). The non-responder patients however, had significantly higher Treg A and lower Treg 
B compared to responder patients (63.5%±4.5 v 38.8%±5.0, p<0.005 for Treg A, 28.9%±2.7 v 
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48.8%±6.1, p<0.05 for Treg B). Error bars are standard error of mean. Kruskal–Wallis one-way 
ANOVA test was used for statistical analysis.  
**** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05 
F) The overlap between the Treg subpopulations which were identified using viSNE and manually 
gated Treg populations based on CD45RA and FOXP3 expression. While subpopulation A and B 
mainly overlap with subpopulations I (CD45RAhi, FOXP3lo) and II (CD45RAlo, FOXP3hi) 
respectively, subpopulation III (CD45RAlo, FOXP3lo) was spread over population B as well as 
outside Treg area.  
Figures are overlay of manually gated Treg populations on viSNE plot of total CD4+ T cells from 
an IST responder AA patient. 
 
Figure 3. PMA/Ionomycin stimulated Treg and Tcon subpopulations: PBMCs from 16 patients and 
5 HDs were stimulated for 4 hours with PMA (Phorbol 12-Myristate 13-Acetate) and a calcium 
ionophore (Ionomycin) and the protein transport inhibitor (Brefeldin A) and stained with a panel 
of antibodies based on 29 surface markers, transcription factors and cytokines (table 1s). Treg 
subpopulations A and B were identified within Tregs after stimulation with Treg profiles that 
distinguished responders from non-responders to IST (figure S3).  
A) Following 4 hours stimulation with PMA and ionomycin in the presence of brefeldin, PBMCs 
were stained for surface and intracellular markers (supplementary table 1, panel 2) followed by 
mass-cytometry and viSNE on CD4+ T cells.  Cytokine secreting CD4+ T cells including IFN- , 
IL-2, IL-17 and IL-4 secreting cells localized distinctly with minimal overlap and outside “Treg’s 
area”. Both Treg A and Treg B populations show higher expression of IL-10 compared to “non-
Tregs” and TNF-α secreting Tregs but there was no significant difference between Tregs A and 
Treg B in terms of IL-10 expression. 
B) Unlike the rest of cytokine secreting CD4+ T cells, TNF-α secreting cells were spread over 
several areas including Treg A subpopulation (red arrow). 
C) Spanning-tree progression analysis of density-normalized events (SPADE) analysis of Treg A 
and B following 4 hours stimulation with PMA/Ionomycin stimulation and intracellular staining 
(supplementary table 1, panel 2). While the TNF-α secreting cells within Treg A subpopulation 
reduces following IST in responder AA patients, there is no similar reduction in non-responder 
patients (patient AA-11 is an IST non-responder and AA-6 is a responder patient). 
D & E) SPADE clustering based on CD45RA, CD45RO, CD27 and CD62L. The Tcon 
subpopulations were
 
defined as naïve (CD45RA+ CD45RO- CD27hi), memory (CD45RA- 
CD45RO+ CD27lo), central memory (CD45RA- CD45RO+ CD27lo CD62Lhi), effector memory 
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(CD45RA- CD45RO+ CD27lo CD62Llo), effector (CD45RA- CD45RO+ CD27lo) and terminal 
effectors (CD45RA- CD45RO- CD27lo). Tcon with effector phenotype express higher CD161 in 
non-responder patients at time of diagnosis compared to responder AA patients. (patient AA-11 is 
an IST non-responder and AA-6 is a responder patient). The frequencies of these subpopulations 
were not significantly different between IST responder and IST non-responder patients at time of 
diagnosis. The naïve Tcon from IST non-responder patients were expressing slightly higher CCR4 
compared to responder patients (see table s2). 
Figure 4. Function and ontogeny of Treg subpopulations 
A) Suppression of Tcon cytokine secretion by Treg subpopulations: CD4+CD25hi CD127lo CD45-
RAhi, CD95-, CCR4lo (subpopulation A), CD4+CD25hi CD127lo CD45-RAlo CD95+ CCR4hi 
(subpopulation B) and CD4+CD25low Tcon were sorted (FacsAria) and cultured for five days with 
anti CD3/CD28 beads (Tcon:Treg:bead = 20:20:1). After five days of culture, the supernatant was 
analyzed with ProcartaPlex 6 Plex (eBioscience) according to the manufacturer’s instructions. The 
cytokine concentrations were corrected for the cell number. Tregs B were able to significantly 
reduce both IFN-  and TNF-α secretion by Tcon (p<0.05) in a 1:1 co-culture. Average of 3 
replicates, student t test, *P < 0.05. Error bars are standard error of mean. 
B) Pairwise comparison of TCR repertoire overlaps. The color shading reflects the numerical 
value of the Power Geometric (PG) indices. The TCR sequences which are shared between Tcon, 
Treg A and Treg B were very low with PG index less than 0.001 in all comparisons. 
C&D) Gene expression profile (GEP) of Treg A and Treg B subpopulations compared to Tcon: We 
have used the published GEP profile of Tregs (Ferraro et al.) as the reference list and all three T-
cell populations were compared to the list which is sorted based on highly expressed genes in 
human Treg. Both Treg A and Treg B subpopulations were enriched with Treg related genes, in 
particular IKZF2, FCRL3, FOXP3, CTLA4 and IL-2R. However, the genes which are expressed at 
lower level in human Tregs were enriched in Tcon but non of the Treg subpopulations (D) The 
frequency of common genes between Treg A, Treg B and references published genes (Ferraro, et 
al) are demonstrated in figure (E) (figure E includes genes which are highly expressed by human 
Tregs).   
Figure 5. 
A) Tregs from both AA patients and healthy donors were sensitive to IL-2 (at 0.5U/mL and 
1U/mL concentration) as evident STAT5 phosphorylation after 15 and 30 minutes. Flow-
cytometry result representative of 8 experiments (two HDs and six AA patients).  
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B) Expanded Tregs were >90% FOXP3 positive following expansion. C) There was no significant 
difference between AA and HD Tregs in terms of fold change increase after 4 weeks expansion 
(represents median fold increase of 3 HDs and 3 AA). Error bars are standard error of mean.   
D) Expanded Tregs were able to suppress Tcon proliferation in both autologous and allogeneic 
settings (criss-cross assay) (1:1 Treg/Tcon ratio after 96 hours culture). It is noticeable that in this 
experiments, TconAA were proliferating slightly more than TconHD in the presence of expanded 
Tregs (6.43% v 3.86%), however this difference was not statistically significant when all 
replicates were compared.  
Tcon were stained by violet proliferation dye (VPD). TconAA: conventional T cells from AA 
patients, TconHD: conventional T cells from healthy donors, TreAA: expanded Tregs from AA 
patients, TreHD: expanded Tregs from healthy donors.  
 
Figure 6. 
A) Overview of the human FOXP3 gene locus with the exon/intron structure in blue and the 
TSDR region in red. The lower panel shows the methylation statues of TSDR in HD and AA 
expanded Tregs compared to non-Tregs. 
B) Expanded Tregs were polyclonal in both AA and HD. The normalized Shannon entropy of 
expanded Treg repertoire was used to calculate the degree of clonality which on average was 0.12.  
C) As we did not succeed to isolate enough Tregs A and Treg B from AA patients for individual 
in-vitro expansion, due to low number of Tregs in these patients, the composition of in-vitro 
expanded Tregs were assesses by calculating the Euclidian distance between the mean expression 
for each parameter in Treg A and B was calculated in 24 Treg A, B (5 HDs and 19 AA samples) 
and 5 (2 AA and 3 HDs) in-vitro expanded Tregs. B cells were used as an irrelevant control. The 
following parameters which showed the highest differences between subpopulations were used for 
the Euclidian distance calculation: FOXP3, CD25, CD127, CD45RA, HLA-DR, CCR6, CCR4, 
CD69, CD27, CXCR3, CD45RO, CD4, CD20, CD95, CD161, CD28, CD152, CD7, CD279, and 
CD19. t-SNE1 and t-SNE2 were used for distance calculation (see also figure S10).   
viSNE plot of expression centroids for all Treg cell subpopulations, B cells and expanded Tregs 
across all samples. Treg A and Treg B were automatically gated from 24 individual samples (19 
samples from AA patients, 5 HDs) using the automated clustering algorithm FLOCK on a subset 
of 700,000 cells proportionally selected from all samples. B cells were gated from the same 24 
samples in Cytobank. Expanded Tregs were from 3 HDs and 2 AA patients. Expression centroids 
were computed for each cell population and used as input for the dimensionality algorithm t-SNE 
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as implemented in the tool cyt (see Materials & Methods for more details). Each dot in the plot 
represents one particular cell population in a particular sample. Expression values were asinh-
transformed using a cofactor of 5. Using a one tail Welch Two Sample T-test we can reject the 
null hypothesis that the distance between Treg A and expanded Tregs is lower than Treg B (p<2.2 
x 10-16) which suggests that expanded Tregs are more similar to subpopulation B than A. 
 
 
Figure 7. 
Graphical abstract: AA patients with higher number of Treg B prior to IST are more likely to 
respond to therapy. Following response to IST, responder patients have higher number of Treg B 
compared to non-responders. Treg B are enriched with cell-cycle related proteins and more likely 
to enter the cell-cycle compared to Treg A subpopulations. In-vitro expanded Tregs are also 
phenotypically closer to Tregs B than Treg A. 
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